02511.HK
HighTide Therapeutics Inc
HKSE · Healthcare · Biotechnology · CN
HKD 3.30
+5.60%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +45.8%
- EBIT
- +45.8%
- EPS
- +16.9%
- Free cash flow
- +81.2%
- Operating cash flow
- +80.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +49.9%
- EBIT
- +49.7%
- Net income
- +35.8%
- EPS
- +39.3%
- Free cash flow
- +44.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026